Increased stiffness in the colon may encourage the development and progression of early-onset colorectal cancer, a new study ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD ...

32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 ...

The National Football League Alumni Association (NFL Alumni) and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control have expanded the "GEAR UP Against ...

After being diagnosed with an extremely rare form of cancer and being told he had 12 to 18 months to live, Alex Villalta ...

Common preservatives used to keep food safe and extend shelf life may be linked to a higher risk of several cancers and type ...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced ...

In return for $10 million upfront, Foresee sold the global rights for its MMP-12 inhibitor programs to Primevera Therapeutics ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Xencor, Inc. (NASDAQ:XNCR) reported its shares moved lower Thursday. The company, a clinical-stage biopharmaceutical concern developing engineered antibodies for the treatment of cancer and autoimmune ...